Yazar "Bolondi, L." seçeneğine göre listele
Listeleniyor 1 - 3 / 3
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Assessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)(Oxford Univ Press, 2018) Blanc, J. F.; Meyer, T.; Cheng, A-L.; El-Khoueiry, A. B.; Cicin, I.; Chen, Y.; Bolondi, L.[Abstract Not Available]Öğe Association of adverse events (AEs) with efficiacy outcomes for Cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase 3 CELESTIAL trial(Karger, 2019) Trojan, J.; Abou-Alfa, G. K.; Meyer, T.; Cheng, A. -L.; Cicin, I.; Bolondi, L.; Kluempen, H. J.[Abstract Not Available]Öğe Association of adverse events with efficacy outcomes for cabozantinib in patients with advanced hepatocellular carcinoma in the Phase III CELESTIAL trial(Wiley, 2019) Strasser, S.; Abou-Alfa, G.; Meyer, T.; Cheng, A.; Cicin, I.; Bolondi, L.; Klumpen, H.[Abstract Not Available]
